For this, immune response is necessary but not sufficient for treatment efficacy. "Although reported results are conclusive in terms of immunological response, it is the samples defined in the clinical protocol that are the basis for the final conclusion. "
Haven't seen clinical protocol to understand what drives final conclusion from Phase I/II clinical.
As you said, it is apparently limited as "cure" per se but targeted to prevent metastases.
Since RhoC is not overexpressed in the primary tumour, the product developed by RhoVac will be used in combination with other therapies focussing on the primary tumour.”The primary tumour will be removed by e.g. surgery, radio- or chemotherapy and the metastases will be prevented or limited using our therapeutic cancer vaccine.”
http://www.naringsliv.se/tidningar/2017-1/life-science/life-science/rhovac-eliminates-metastatic-cancer-cells/